PA
LFCR icon

PharVision Advisers’s Lifecore Biomedical LFCR Stock Holding History

PharVision Advisers’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,041
Closed -$156K – 400
2025
Q4 		$156K Sell
19,041
-1,469
-7% -$10.9K 0.08% 608
2025
Q3 		$151K Buy
+20,510
New +$155K 0.08% 571

Other funds holding LFCR

2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GC
Grizzlyrock Capital Chicago, Illinois $143M AUM 6.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PharVision Advisers's LFCR Position: Q1 2026 in Review

PharVision Advisers sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 19,041 shares — an estimated $156K sold.

PharVision Advisers first reported a position in LFCR in Q3 2025 and held it in 2 quarters. The position peaked at $156K in Q4 2025. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • PharVision Advisers reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 19,041 Lifecore Biomedical shares in Q1 2026, an estimated $156K.
  • PharVision Advisers first reported a position in Lifecore Biomedical in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Lifecore Biomedical position peaked at $156K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.